PAP
PCVX icon

Persistent Asset Partners’s Vaxcyte PCVX Stock Holding History

Persistent Asset Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Buy
+125
New +$6.79K 0.01% 543
2025
Q2 		– Sell
-119
Closed -$335K – 224
2025
Q1 		$335K Buy
+119
New +$9.51K 0.28% 76

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Persistent Asset Partners's PCVX Position: Q2 2026 in Review

Persistent Asset Partners increased its Vaxcyte (PCVX) stake by 184% in Q2 2026, buying an estimated $532K and bringing the position to 15,105 shares worth $878K. The position accounts for 0.26% of the portfolio, ranked #70.

Persistent Asset Partners first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.8M in Q3 2025. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Persistent Asset Partners held 15,105 shares of Vaxcyte worth $878K as of Q2 2026.
  • Persistent Asset Partners bought 9,786 Vaxcyte shares in Q2 2026, an estimated $532K.
  • Vaxcyte made up 0.26% of Persistent Asset Partners's portfolio in Q2 2026, its #70 holding.
  • Persistent Asset Partners first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
  • Persistent Asset Partners's Vaxcyte position peaked at $1.8M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.